Skip to content
10-K

Annual Report

CNS Pharmaceuticals, Inc. CNSP

0001683168-26-002550

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 31, 2026 811.45K sh
Shares Diluted FY 2025 · Dec 31, 2025 443.37K sh
Shares Diluted restated FY 2025 · Dec 31, 2024 31.82K sh
Capex FY 2025 · Dec 31, 2025 $18.18K
Capex FY 2025 · Dec 31, 2024 $4.19K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$13.81M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$17.11M
Cash And Equivalents FY 2025 · Dec 31, 2025 $7.2M
Cash And Equivalents FY 2025 · Dec 31, 2024 $6.46M
Stockholders Equity FY 2025 · Dec 31, 2025 $4.52M
Stockholders Equity FY 2025 · Dec 31, 2024 $6.18M
Stockholders Equity FY 2025 · Dec 31, 2023 −$4.43M
Current Liabilities FY 2025 · Dec 31, 2025 $4.1M
Current Liabilities FY 2025 · Dec 31, 2024 $2.52M
Total Liabilities FY 2025 · Dec 31, 2025 $4.1M
Total Liabilities FY 2025 · Dec 31, 2024 $2.52M
Current Assets FY 2025 · Dec 31, 2025 $8.1M
Current Assets FY 2025 · Dec 31, 2024 $8.66M
Total Assets FY 2025 · Dec 31, 2025 $8.62M
Total Assets FY 2025 · Dec 31, 2024 $8.7M
Eps Diluted FY 2025 · Dec 31, 2025 −$35.75
Eps Diluted restated FY 2025 · Dec 31, 2024 −$466.89
Eps Basic FY 2025 · Dec 31, 2025 −$35.75
Eps Basic restated FY 2025 · Dec 31, 2024 −$466.89
Sga Expense FY 2025 · Dec 31, 2025 $6.21M
Sga Expense FY 2025 · Dec 31, 2024 $5.61M
Rd Expense FY 2025 · Dec 31, 2025 $9.77M
Rd Expense FY 2025 · Dec 31, 2024 $9.29M
Net Income FY 2025 · Dec 31, 2025 −$15.85M
Net Income FY 2025 · Dec 31, 2024 −$14.86M
Operating Income FY 2025 · Dec 31, 2025 −$15.99M
Operating Income FY 2025 · Dec 31, 2024 −$14.9M